文献速递眼底病与葡萄膜炎

欧洲年龄相关性黄斑变性的患病率:过去与未来

Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.
PubMed 文献 · Ophthalmology · 2017-07-14

该研究基于欧洲眼流行病学(E3)联盟14项人群队列、10个国家、42080名40岁及以上个体,采用随机效应Meta分析估算1990至2013年早期与晚期年龄相关性黄斑变性(AMD)患病率。早期AMD患病率随年龄从3.5%升至17.6%,晚期AMD从0.1%升至9.8%;2006年后晚期AMD患病率下降,但预计到2040年患病人数仍将接近翻倍。

要点

  • 早期AMD患病率从55-59岁的3.5%升至≥85岁的17.6%,晚期AMD从0.1%升至9.8%。
  • 2006年后晚期AMD患病率下降,70岁以后最为明显;2006年后晚期AMD中脉络膜新生血管(CNV)患者视力受损减少(P = 0.016)。

核心结论

  • 过去20年欧洲AMD患病率下降,CNV患者视力改善,健康生活方式与抗血管内皮生长因子治疗的实施是最可能的解释。
  • 尽管患病率下降,未来20年受累人数仍将大幅增加,AMD仍是欧洲人的重要公共卫生问题。

研究设计与样本

  • 研究设计为患病率数据的Meta分析。
  • 共纳入欧洲10个国家14项人群队列中42080名40岁及以上个体。
  • AMD依据眼底照相采用Rotterdam分类诊断,早期与晚期AMD患病率采用随机效应Meta分析,按年龄、出生队列、性别、地理区域和研究时间段分层计算。

主要发现

  • 早期AMD患病率从55-59岁的3.5%(95%CI 2.1%-5.0%)升至≥85岁的17.6%(95%CI 13.6%-21.5%)。
  • 晚期AMD患病率从55-59岁的0.1%(95%CI 0.04%-0.3%)升至≥85岁的9.8%(95%CI 6.3%-13.3%)。
  • 2006年后观察到晚期AMD患病率下降,70岁以后最为明显。
  • 除最年长年龄组的晚期AMD外,各年龄组性别间患病率相近;发现北欧CNV患病率较高的趋势。
  • 2006年后,伴有CNV的眼数和≥80岁伴有CNV的受试者中视力受损者均减少(P = 0.016)。

关键数值与推荐

  • 早期AMD患病率:55-59岁3.5%(95%CI 2.1%-5.0%),≥85岁17.6%(95%CI 13.6%-21.5%)。
  • 晚期AMD患病率:55-59岁0.1%(95%CI 0.04%-0.3%),≥85岁9.8%(95%CI 6.3%-13.3%)。
  • 2006年后伴有CNV的眼和≥80岁伴有CNV的受试者视力受损减少,P = 0.016。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Age-related macular degeneration (AMD) is a frequent, complex disorder in elderly of European ancestry. Risk profiles and treatment options have changed considerably over the years, which may have affected disease prevalence and outcome. We determined the prevalence of early and late AMD in Europe from 1990 to 2013 using the European Eye Epidemiology (E3) consortium, and made projections for the future. DESIGN: Meta-analysis of prevalence data. PARTICIPANTS: A total of 42 080 individuals 40 years of age and older participating in 14 population-based cohorts from 10 countries in Europe. METHODS: AMD was diagnosed based on fundus photographs using the Rotterdam Classification. Prevalence of early and late AMD was calculated using random-effects meta-analysis stratified for age, birth cohort, gender, geographic region, and time period of the study. Best-corrected visual acuity (BCVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV). MAIN OUTCOME MEASURES: Prevalence of early and late AMD, BCVA, and number of AMD cases. RESULTS: Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%-5.0%) in those aged 55-59 years to 17.6% (95% CI 13.6%-21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%-0.3%) and 9.8% (95% CI 6.3%-13.3%), respectively. We observed a decreasing prevalence of late AMD after 2006, which became most prominent after age 70. Prevalences were similar for gender across all age groups except for late AMD in the oldest age category, and a trend was found showing a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer ≥80-year-old subjects with CNV were visually impaired (P = 0.016). Projections of AMD showed an almost doubling of affected persons despite a decreasing prevalence. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, and for late AMD between 3.9 and 4.8 million. CONCLUSION: We observed a decreasing prevalence of AMD and an improvement in visual acuity in CNV occuring over the past 2 decades in Europe. Healthier lifestyles and implementation of anti-vascular endothelial growth factor treatment are the most likely explanations. Nevertheless, the numbers of affected subjects will increase considerably in the next 2 decades. AMD continues to remain a significant public health problem among Europeans.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017. PMID: 28712657. doi:10.1016/j.ophtha.2017.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。